Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice

International Journal of Medical Microbiology

Volumn 297, Issue 3, 2007, Pages 151-162

  Stritzker, Jochen ^a   Weibel, Stephanie ^b,c   Hill, Philip J ^a   Oelschlaeger, Tobias A ^d   Goebel, Werner ^c   Szalay, Aladar A ^a,b,c  

^a GENELUX CORPORATION   (United States)

^b Virchow Center Biomedical Research School of Medicine   (Germany)

^c Institute of Biochemistry   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

E. coli Nissle 1917; l arabinose induced gene expression; Probiotic; Tissue distribution; Tumor targeting

Indexed keywords

PROBIOTIC AGENT; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CELL DIVISION; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROINVASIVE ESCHERICHIA COLI; ESCHERICHIA COLI; FEMALE; GENE AMPLIFICATION; GENE INDUCTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; LIVER; MOUSE; NONHUMAN; PATHOGENESIS; SALMONELLA TYPHIMURIUM; SOLID TUMOR; SPLEEN; TISSUE DISTRIBUTION; TUMOR; TUMOR NECROSIS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 34247618171     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2007.01.008     Document Type: Article

References (48)

1. Agrawal N., Bettegowda C., Cheong I., Geschwind J.F., Drake C.G., Hipkiss E.L., Tatsumi M., Dang L.H., Diaz Jr. L.A., Pomper M., Abusedera M., Wahl R.L., Kinzler K.W., Zhou S., Huso D.L., and Vogelstein B. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA 101 (2004) 15172-15177
2. Altenhöfer A., Oswald S., Sonnenborn U., Enders C., Schulze J., Hacker J., and Ölschläger T.A. The probiotic E. coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol. Med. Microbiol. 40 (2004) 223-229
3. Blum G., Marre R., and Hacker J. Properties of E. coli strains of serotype O6. Infection 23 (1995) 234-236
4. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., Cohen D., Robin G., Fontaine-Thompson A., Sansonetti P.J., and Hale T.L. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67 (1999) 3437-3443
5. Cunningham C., and Nemunaitis J. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Hum. Gene Ther. 12 (2001) 1594-1596
6. Dang L.H., Bettegowda C., Huso D.L., Kinzler K.W., and Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. USA 98 (2001) 15155-15160
7. Dresselaers T., Theys J., Nuyts S., Wouters B., de Bruijn E., Anne J., Lambin P., Van Hecke P., and Landuyt W. Non-invasive 19F MR spectroscopy of 5-fluorocytosine to 5-fluorouracil conversion by recombinant Salmonella in tumours. Br. J. Cancer 89 (2003) 1796-1801
8. Ebbell B. The Greatest Egyptian Medical Document (translated by B. Ebell) (1937), Munksgaard and Oxford University Press, Copenhagen, Denmark
9. Fisher B., Brown A., Wolmark N., Fisher E.R., Redmond C., Wickerham D.L., Margolese R., Dimitrov N., Pilch Y., Glass A., et al. Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer. Eight-year results from the National Surgical Adjuvant Breast and Bowel Project B-10. Cancer 66 (1990) 220-227
10. Gericke D., and Engelbart K. Oncolysis by clostridia. II. Experiments on a tumor spectrum with a variety of clostridia in combination with heavy metal. Cancer Res. 24 (1964) 217-221
11. Gots R.E., Formal S.B., and Giannella R.A. Indomethacin inhibition of Salmonella typhimurium, Shigella flexneri, and cholera-mediated rabbit ileal secretion. J. Infect. Dis. 130 (1974) 280-284
12. Grozdanov L., Zähringer U., Blum-Öhler G., Brade L., Henne A., Knirel Y.A., Schombel U., Schulze J., Sonnenborn U., Gottschalk G., Hacker J., Rietschel E.T., and Dobrindt U. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of E. coli strain Nissle 1917. J. Bacteriol. 184 (2002) 5912-5925
13. Guzman L.M., Belin D., Carson M.J., and Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J. Bacteriol. 177 (1995) 4121-4130
14. Hale T.L., Sansonetti P.J., Schad P.A., Austin S., and Formal S.B. Characterization of virulence plasmids and plasmid-associated outer membrane proteins in Shigella flexneri, Shigella sonnei, and E. coli. Infect. Immun. 40 (1983) 340-350
15. Hoption Cann S.A., van Netten J.P., and van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J. 79 (2003) 672-680
16. Hurst J., Maniar N., Tombarkiewicz J., Lucas F., Roberson C., Steplewski Z., James W., and Perras J. A novel model of a metastatic human breast tumour xenograft line. Br. J. Cancer 68 (1993) 274-276
17. Khlebnikov A., Datsenko K.A., Skaug T., Wanner B.L., and Keasling J.D. Homogeneous expression of the P(BAD) promoter in E. coli by constitutive expression of the low-affinity high-capacity AraE transporter. Microbiology 147 (2001) 3241-3247
18. Kimura N.T., Taniguchi S., Aoki K., and Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40 (1980) 2061-2068
19. King I., Bermudes D., Lin S., Belcourt M., Pike J., Troy K., Le T., Ittensohn M., Mao J., Lang W., Runyan J.D., Luo X., Li Z., and Zheng L.M. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent. Hum. Gene Ther. 13 (2002) 1225-1233
20. Klebanoff C.A., Gattinoni L., and Restifo N.P. CD8 T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211 (2006) 214-224
21. Lee C.H., Wu C.L., and Shiau A.L. Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J. Gene Med. 6 (2004) 1382-1393
22. Lee C.H., Wu C.L., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. Cancer Gene Ther. 12 (2005) 175-184
23. Lee C.H., Wu C.L., Tai Y.S., and Shiau A.L. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol. Ther. 11 (2005) 707-716
24. Lee K.C., Zheng L.M., Margitich D., Almassian B., and King I. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and E. coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent. Int. J. Toxicol. 20 (2001) 207-217
25. Lemmon M.J., van Zijl P., Fox M.E., Mauchline M.L., Giaccia A.J., Minton N.P., and Brown J.M. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 4 (1997) 791-796
26. Lodinova-Zadnikova R., and Sonnenborn U. Effect of preventive administration of a nonpathogenic E. coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol. Neonate 71 (1997) 224-232
27. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., Ash O., Carmichael E., Chakraborty A., Fischer J., Lin S.L., Luo X., Miller S.I., Zheng L., King I., Pawelek J.M., and Bermudes D. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 17 (1999) 37-41
28. Malmgren R.A., and Flanigan C.C. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res. 15 (1955) 473-478
29. Moese J.R., and Moese G. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res. 24 (1964) 212-216
30. Nemunaitis J., Cunningham C., Senzer N., Kuhn J., Cramm J., Litz C., Cavagnolo R., Cahill A., Clairmont C., and Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther. 10 (2003) 737-744
31. Parker R.C., Plummer H.C., Siebenmann C.O., and Chapman M.G. Effect of histolyticus infections and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. 66 (1947) 461-467
32. Pawelek, J.M., 2005. Use of Salmonella and Bordetella for targeting and destruction of tumor cells. In: Life Engineering Symposium University of California, San Francisco, Mission Bay Campus, August 19-20, 2005, 〈http://www.keckfutures.org/site/DocServer/life_eng_pawelek_abstract.pdf?docID=561〉.
33. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57 (1997) 4537-4544
34. Pawelek J.M., Sodi S., Chakraborty A.K., Platt J.T., Miller S., Holden D.W., Hensel M., and Low K.B. Salmonella pathogenicity island-2 and anticancer activity in mice. Cancer Gene Ther. 9 (2002) 813-818
35. Pawelek J.M., Low K.B., and Bermudes D. Bacteria as tumour-targeting vectors. Lancet Oncol. 4 (2003) 548-556
36. Qazi S.N., Counil E., Morrissey J., Rees C.E., Cockayne A., Winzer K., Chan W.C., Williams P., and Hill P.J. agr expression precedes escape of internalized Staphylococcus aureus from the host endosome. Infect. Immun. 69 (2001) 7074-7082
37. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T. Non-pathogenic E. coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
38. Soghomonyan S.A., Doubrovin M., Pike J., Luo X., Ittensohn M., Runyan J.D., Balatoni J., Finn R., Tjuvajev J.G., Blasberg R., and Bermudes D. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 12 (2005) 101-108
39. Sörensen M., Lippuner C., Kaiser T., Mißlitz A., Aebischer T., and Bumann D. Rapidly maturing red fluorescent protein variants with strongly enhanced brightness in bacteria. FEBS Lett. 552 (2003) 110-114
40. Sun J., Gunzer F., Westendorf A.M., Buer J., Scharfe M., Jarek M., Gossling F., Blocker H., and Zeng A.P. Genomic peculiarity of coding sequences and metabolic potential of probiotic E. coli strain Nissle 1917 inferred from raw genome data. J. Biotechnol. 117 (2005) 147-161
41. Thiele E.H., Arison R.N., and Boxer G.E. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res. 24 (1964) 222-233
42. Welch R.A., Burland V., Plunkett III G., Redford P., Roesch P., Rasko D., Buckles E.L., Liou S.R., Boutin A., Hackett J., Stroud D., Mayhew G.F., Rose D.J., Zhou S., Schwartz D.C., Perna N.T., Mobley H.L., Donnenberg M.S., and Blattner F.R. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic E. coli. Proc. Natl. Acad. Sci. USA 99 (2002) 17020-17024
43. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Sem. Cancer Biol. 16 (2006) 3-15
44. Yazawa K., Fujimori M., Amano J., Kano Y., and Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 7 (2000) 269-274
45. Yi C., Huang Y., Guo Z.Y., and Wang S.R. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma. Acta Pharmacol. Sinica 26 (2005) 629-634
46. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., Goebel W., and Szalay A.A. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol. 22 (2004) 313-320
47. Zhao M., Yang M., Li X.M., Jiang P., Baranov E., Li S., Xu M., Penman S., and Hoffman R.M. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 102 (2005) 755-760
48. Zhao M., Yang M., Ma H., Li X., Tan X., Li S., Yang Z., and Hoffman R.M. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 66 (2006) 7647-7652